Condition
Pulmonary Hypertension Associated With HFpEF
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
100%
3 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 3 (3)
Trial Status
Recruiting1
Terminated1
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07436689Phase 3Enrolling By InvitationPrimary
Long-Term Open-Label Extension Study of Oral Levosimendan
NCT07288398Phase 3RecruitingPrimary
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT03043651Phase 3TerminatedPrimary
Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF
Showing all 3 trials